E2F1 and neoplasm: We show that E2F1 transactivates the aerobic glycolysis regulator SLC16A1/MCT1 in parallel with its antisense lncRNA-SLC16A1-AS1 via a shared E2F1-responsive promoter, an event that is particularly associated with tumor progression to muscle-invasive stages and poor patient outcomes.